RADIOIMMUNOTHERAPY AND EXTRACORPOREAL ADSORPTION THERAPY STUDIES IN MACAQUES

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 该项目的总体目标是通过使用放射性标记的单抗(放射免疫疗法，RIT)向目标淋巴造血组织提供补充辐射，改善非霍奇金淋巴瘤和急性白血病患者的干细胞移植结果。靶向方法的改进可能允许将更大剂量的放射性从抗体输送到白血病和淋巴瘤细胞，同时将较低剂量的辐射输送到正常器官，从而导致更高的治愈率和更少的治疗相关毒性。这些非人类灵长类动物研究的具体目标是： 评估在猕猴体内注射放射性标记生物素抗体，然后进行体外吸附的可行性、安全性和毒性。 2.评估体外吸附疗法(ECAT)对猕猴体内放射性标记生物素抗体的药代动力学和生物分布的影响。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The overall goal of this project is to improve the outcome of stem cell transplantation for patients with non-Hodgkin's lymphoma and acute leukemia by delivering supplemental radiation to target lymphohematopoietic tissues using radiolabeled monoclonal antibodies (radioimmunotherapy, RIT). The improvement of targeting methods may allow the delivery of larger doses of radioactivity from antibody to leukemia and lymphoma cells, while delivering lower radiation doses to normal organs, resulting in higher cure rates and less treatment-related toxicity. The specific aims in these non-human primate studies are: a. To evaluate the feasibility, safety, and toxicity of administering radiolabeled-biotinylated antibodies followed by extracorporeal adsorption in macaques. b. To assess the impact of extracorporeal adsorption therapy (ECAT) on the pharmacokinetics and biodistribution of radiolabeled-biotinylated antibodies in macaques.